Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey
Por:
Narvaez, J, Oton, T, Calvo-Alen, J, Escudero-Contreras, A, Munoz-Fernandez, S, Rodriguez-Heredia, J, Romero-Yuste, S, Vela-Casasempere, P, Lujan, S, Baquero, J and Carmona, L
Publicada:
1 jul 2021
Ahead of Print:
6 mar 2021
Resumen:
Objectives: To explore current evidence on the management of poor prognostic factors in rheumatoid arthritis (RA) and to investigate whether this evidence is taken into account by clinicians when deciding on treatment in daily clinical practice.
Methods: We performed a systematic literature review (SLR) to analyse the effects of currently available biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) on the classically accepted poor prognostic factors of RA. All randomized controlled trials reporting subgroup analyses about effects on prognostic factors were identified and synthesized. In a second phase, a two round Delphi survey was carried out to contrast the SLR results with the grade of agreement of a large group of rheumatologists about the effectiveness of each drug class on each prognostic factor.
Results: According to the Delphi results, the only prognostic factor that significantly influenced the selection of treatment was the presence of interstitial lung disease (ILD), being the preferred treatment in this scenario abatacept or rituximab. The rest of the poor prognostic factors (including high disease activity at baseline, disability as measured by the Health Assessment Questionnaire index, seropositivity, elevated acute-phase reactants, and evidence of erosions based on plain radiography or ultrasonography) did not seem to significantly influence rheumatologists when choosing a treatment. The results of the SLR results did not show solid evidence regarding the use of any specific therapy in the management of patients with specific poor factors, except in the case of RA-ILD, although the data in the literature in this regard are not free of bias.
Conclusions: The only prognostic factor that seems to significantly influence the selection of treatment is the presence of RA-ILD. (C) 2021 Societe francaise de rhumatologie. Published by Elsevier Masson SAS.
Filiaciones:
Narvaez, J:
Hosp Univ Bellvitge, Barcelona, Spain
Oton, T:
Inst Salud Musculoesquelet InMusc, Calle Ofelia Nieto 10, Madrid, Spain
Calvo-Alen, J:
Hosp Univ Alava, Vitoria, Spain
Escudero-Contreras, A:
Univ Cordoba, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
Munoz-Fernandez, S:
European Univ, Hosp Univ Infanta Sofia, Madrid, Spain
Rodriguez-Heredia, J:
Hosp Univ Getafe, Madrid, Spain
Romero-Yuste, S:
Complejo Hosp Univ Pontevedra, Pontevedra, Spain
:
Hosp Gen Univ Alicante, Alicante, Spain
Lujan, S:
Bristol Myers Squibb, Med Dept, Madrid, Spain
Baquero, J:
Scientia Salus, Madrid, Spain
Carmona, L:
Inst Salud Musculoesquelet InMusc, Calle Ofelia Nieto 10, Madrid, Spain
Open Access
FULL TEXT
 |
Published Version |
|
| No Accesible |
|